Click to open contact form.
Your Global Partners in the Business of Innovation

Representing BiondVax Pharmaceuticals

Publications / Jun 29, 2017

Senior Partner Ilan Gerzi represented BiondVax Pharmaceuticals Ltd. (NASDAQ, TLV: BVXV), an Israeli biopharma company developing a universal vaccine for all strains of influenza, in the signing of an agreement with the European Investment Bank (EIB) for a €20 million loan. The money will be used to fund a Phase III trial for BiondVax’s product. The company’s share price jumped 2.25% on the news today, boosting its market cap to NIS 123 million.

CLICK HERE to read more.

INNOVATION HIGHLIGHTS